References
- Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye. 2020;34(11):1966–1972. doi:10.1038/s41433-020-0895-z
- Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet Lond Engl. 2022;399(10326):729–740. doi:10.1016/S0140-6736(22)00010-1
- Maguire MG, Martin DF, Ying GS, et al.; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. 5-Year outcomes with anti-VEGF treatment of neovascular age-related Macular Degeneration (AMD): the comparison of AMD treatments trials. Ophthalmology. 2016;123(8):1751–1761. doi:10.1016/j.ophtha.2016.03.045
- American Society of Retina Specialists. 2020 membership survey preferences and trends; 2020. Available from: https://www.asrs.org/content/documents/_2020-pat-survey-results-for-website.pdf. Accessed May 1, 2023.
- Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050–1059. doi:10.1016/j.ophtha.2020.11.011
- Kunimoto D, Yoon YH, Wykoff CC, et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. 2020;127(10):1331–1344. doi:10.1016/j.ophtha.2020.03.035
- Khurana RN, Kunimoto D, Yoon YH, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2021;128(7):1027–1038. doi:10.1016/j.ophtha.2020.11.017
- Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47(3):1236–1240. doi:10.1167/iovs.05-0981
- Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015;29(6):721–731. doi:10.1038/eye.2015.48
- Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92(8):713–723. doi:10.1111/aos.12463
- Stanga PE, Valentín-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye. 2023;1–8. doi:10.1038/s41433-023-02505-z
- Pauleikhoff D, Löffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2002;240(7):533–538. doi:10.1007/s00417-002-0505-8
- Gelisken F, Ziemssen F, Voelker M, Bartz-Schmidt KU, Inhoffen W. Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye. 2009;23(3):694–702. doi:10.1038/sj.eye.6703098
- Gabrielle PH, Maitrias S, Nguyen V, et al. Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB registry. Acta Ophthalmol. 2022;100(8):e1569–e1578. doi:10.1111/aos.15137
- Meredith TA, McCannel CA, Barr C, et al. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2015;122(4):817–821. doi:10.1016/j.ophtha.2014.10.027
- Meer EA, Oh DH, Brodie FL. Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons. Clin Ophthalmol Auckl NZ. 2022;16:4273–4279. doi:10.2147/OPTH.S384995
- Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143(4):679–680. doi:10.1016/j.ajo.2007.02.024
- Fallico M, Lotery AJ, Longo A, et al. Treat and extend versus fixed regimen in neovascular age related macular degeneration: a systematic review and meta-analysis. Eur J Ophthalmol. 2021;31(5):2496–2504. doi:10.1177/1120672120964699
- Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice. Trans Am Ophthalmol Soc. 2009;107:311–324.
- Lim LA, Frost NA, Powell RJ, Hewson P. Comparison of the ETDRS logMAR, ‘compact reduced logMar’ and Snellen charts in routine clinical practice. Eye. 2010;24(4):673–677. doi:10.1038/eye.2009.147